HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection
Open Access
- 18 July 2018
- journal article
- research article
- Published by S. Karger AG in Liver Cancer
- Vol. 8 (1) , 41-65
Abstract
Objective: HCV clearance by current antiviral therapies improves clinical outcomes but falls short in eliminating the risk for hepatocellular carcinoma (HCC) emergence. As the HCC immune surveillance establishment is vital for the control of neoplastic development and growth, we investigated its correlation with on-/post-treatment HCC emergence, and further analyzed the influence of viral eradication on this setup in patients with HCV-related liver cirrhosis. Design: PBMC isolated at baseline and longitudinally during therapy were analyzed for tumor-associated antigen (TAA)-specific CD8+ T cell responses against glypican-3 overlapping peptides in vitro using high-definition flow cytometry. Multianalyte profiling of fifty soluble inflammatory mediators (SIM) in the plasma was also performed using Luminex-based multiplex technology. Results: Cirrhosis patients were characterized by an altered profile of distinct SIMs at baseline. At this time point, immune-surveilling T cells targeting specific HCC-associated antigens were readily detectable in HCV-free cirrhosis patients whilst being rather weak in such patients who further developed HCC upon virus eradication. Therapy-induced cure of HCV infection analogously reduced the strength of the prevailing HCC immune surveillance machinery, particularly by CD8+ T cells in cirrhosis patients. These results were further validated by T cell reactivities to six immuno-dominant HCC-associated HLA-A2-restricted epitopes. Further, we demonstrated that this phenomenon was likely orchestrated by alterations in SIMs – with evidence of IL-12 being a major culprit. Conclusion: Given the relationship between the baseline HCC-specific immune surveilling T cell responses and therapy-associated HCC emergence, and the impact of HCV clearance on its strength and magnitude, we recommend a continued HCC screening in cirrhotic HCV patients despite HCV resolution.Keywords
This publication has 36 references indexed in Scilit:
- Impact of Sustained Virologic Response with Direct‐Acting Antiviral Treatment on Mortality in Patients with Advanced Liver DiseaseHepatology, 2017
- Glypican‐3: A promising biomarker for hepatocellular carcinoma diagnosis and treatmentMedicinal Research Reviews, 2017
- Antitumor CD8+T cells in hepatocellular carcinoma: Present but exhaustedHepatology, 2013
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinomaHepatology, 2013
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinomaHepatology, 2012
- Comprehensive analysis of the α-fetoprotein-specific CD8+ T cell responses in patients with hepatocellular carcinomaHepatology, 2008
- Identification of α‐fetoprotein‐derived peptides recognized by cytotoxic T lymphocytes in HLA‐A24+ patients with hepatocellular carcinomaInternational Journal of Cancer, 2005
- Induction of interferon-γ production in Th1 CD4+ T cells: evidence for two distinct pathways for promoter activationEuropean Journal of Immunology, 1999
- Interleukin‐12 is produced by dendritic cells and mediates T helper 1 development as well as interferon‐γ production by T helper 1 cellsEuropean Journal of Immunology, 1996